Rethinking liver therapy discovery and development
WHAT
Using human models to generate genomic and phenotypic data at scale, we're developing RNA therapies for the biggest liver health challenges.
WHY
Chronic liver disease is the only top ten global killer on the rise.
"Liver disease is the third leading cause of premature death." UK Health Security Agency, July 2021
Chronic liver disease affects millions of patients worldwide, with the prevalence rising. Despite the recent first approval of a therapy for MASH, a high unmet need remains for patients with late stage disease, where for many patients the only treatment remains a liver transplant.
HOW
Human Discovery
We deep phenotype human liver samples and models at scale to causally map genes to cells to histology and clinical data.
Human Validation
Ochre’s validation platform is among the world’s most advanced in human systems, from human cell co-culture, to diseased liver tissue culture, to the perfusion of whole human livers.
RNA Therapies
Our RNA chemistry platform not only develops therapies with a greater chance of clinical success, it allows Ochre’s scientists to progress a target to a validated lead using human data in weeks, not years.
WHO
Built on decades of leading genomics, ML, drug discovery and development experience, Ochre Bio’s scientific teams are committed to addressing unmet needs for patients with chronic liver disease globally.
Anthony Beucher
Yu Chen Chiang
Alex K. Shalek
Eduardo Martins
Leanne Hodson
Michael Hodges
Troy Dale
Scott Friedman
Chas Bountra
Sachin Patil
Michal Matuszewski
Fleur Palmer-Paquis
Robert Mart
Calum Irwin
Nick Taylor
Senior Scientist
Head of Early Validation
Scientist
Scientist
PARTNERS & INVESTORS
